As incoming European markets look towards alternative delivery mechanisms like oils and vaporisers, more mature markets like the UK remain dominated by traditional dried cannabis flower, representing around 80% of all prescriptions.
Originally published on Cannabis Health The Medical Cannabis Clinicians Society (MCCS) has published what it describes as a crucial step forward for standardised prescribing in the UK, a comprehensive guide establishing evidence-based dosing protocols for cannabis oils.
UK medical cannabis operator Kanabo Group has fallen into administration, seeing the last remaining member of the first four cannabis pioneers onto the London Stock Exchange face collapse.
Cannim Group Pty, the international medical cannabis company with operations spanning the UK, Australia, the US and Canada, has entered voluntary administration.
Airo Brands, a US multi-state CPG company focused on proprietary cannabis products, in partnership with Jupiter Research LLC, has received regulatory approval for its CE-marked Class IIa medical handheld liquid inhalation device, the Airo Medical Inhalation System, across Europe and Australia.
Curaleaf Laboratories has been confirmed as headline sponsor of the inaugural Cannabis Health Symposium, taking place on 25 November 2025 at Conway Hall, London.
As Europe’s medical cannabis market shifts from a focus on growth to pharmaceutical discipline, PHCANN International has emerged as a leading voice in this new phase.
The UK’s medical cannabis industry is now the second largest in Europe, second only to Germany, thanks to consistent and sustained growth over the last seven years.
The UK’s cannabis industry, one of the largest on the planet, sits at a crossroads.
